Biotechnology company Revance Therapeutics Inc (Nasdaq:RVNC) revealed on Tuesday that the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under US FDA review for the treatment of glabellar lines in 2021.
Revance said that DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
In conjunction, the company provided its response to the Form 483 and is confident in the quality of its DaxibotulinumtoxinA for Injection BLA submission and continues to anticipate FDA approval in 2021. A Form 483 does not constitute a final agency determination.
Bioeq and Zydus partner for US commercialisation of Lucentis biosimilar NUFYMCO
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation